EmpowerPharm Inc. (Closely Held)

EmpowerPharm Inc.
5575 North Service Road, Suite 603
Burlington, ON, L7L 6M1
Canada
Phone: (416) 291-2580
https://empowerpharm.ca/ 

EmpowerPharm Inc. (“EmpowerPharm” or "the Company") is a Canadian pharmaceutical company dedicated to developing pharmaceutical grade cannabidiol (CBD) therapies in solid oral dose formats. Its primary focus is on advancing treatments for mental health disorders, particularly social anxiety disorder (SAD). The Company applies its proprietary formulations based on Self-Nanoemulsifying Drug Delivery System (SNEDDS) technology to improve the bioavailability of CBD to enhance its therapeutic effectiveness for a more impactful treatment. With promising Phase 2 trial outcomes, the Company is progressing to Phase 3 trials, targeting prescription drug approvals in Canada, the U.S., and select international markets, while preparing for a potential market launch. Phase 2 trials identified an effective CBD dose of 300 mg, prompting the development of new high-bioavailability 150 mg capsules for twice-daily use in Phase 3. EmpowerPharm’s expanding intellectual property (IP) portfolio secures market exclusivity and a competitive edge, supporting its focus on developing new products and indications, including proprietary tablet and soft gel capsule dosage forms. The Company operates state-of-the-art, fully licensed facilities that support both research and development (R&D) as well as the eventual commercial pharmaceutical production. 

* Updated on November 18, 2024.